← Back to catalogue

Pathway HER-2/NEU (Clone CB11) Primary Antibody

FDA PMA

Class III (US FDA PMA)

PMA P990081

by Ventana Medical Systems, Inc.

Identity

Trade Name
PATHWAY ANTI-HCR-2/NCU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY FDA PMA
Generic Name
SYSTEM, TEST, HER-2/NEU, IHC FDA PMA

Identifiers

PMA Number
P990081 FDA PMA
FDA Product Code
MVC FDA PMA

Classification

Device Class
Class III FDA PMA
Advisory Committee
Pathology FDA PMA
FDA Decision
APPR Approved FDA PMA

The Pathway HER-2/NEU (Clone CB11) Primary Antibody is a mouse monoclonal antibody intended for laboratory use in immunohistochemistry (IHC). It is designed for the semi-quantitative detection of c-ERBB-2 antigen in formalin-fixed, paraffin-embedded tissue sections, including both normal and neoplastic samples. This assay aids in the assessment of HER-2/neu expression levels, which is critical for evaluating breast cancer patients for potential HERCEPTIN treatment.

This device is supplied as a reagent for use on Ventana automated immunohistochemistry slide staining systems. It is intended for single-use in a laboratory setting and requires no additional sterilization beyond standard reagent handling. The antibody is classified as a Class III medical device under FDA regulations and holds a Premarket Approval (PMA) designation (PMA Number: P990081). No MRI safety considerations apply, as it is not a physical device but a diagnostic reagent.

Frequently asked questions

What is the Pathway HER-2/NEU (Clone CB11) Primary Antibody used for in clinical practice?

This antibody is designed for **laboratory use in immunohistochemistry (IHC)** to semi-quantitatively detect the **c-ERBB-2 antigen** in formalin-fixed, paraffin-embedded tissue samples—both normal and cancerous. It helps pathologists assess **HER-2/neu expression levels** in breast cancer patients, which is critical for determining eligibility for **HERCEPTIN treatment** (trastuzumab). The assay aids in treatment decision-making by evaluating protein overexpression linked to tumor behavior.

How is the Pathway HER-2/NEU (Clone CB11) Primary Antibody supplied and used in a lab?

The antibody is supplied as a **reagent** specifically for use on **Ventana automated immunohistochemistry slide staining systems**. It is intended for **single-use only** in a laboratory setting and does not require additional sterilization beyond standard reagent handling. The automated system ensures consistent staining of tissue sections, while the antibody itself is not a physical device—it is a diagnostic reagent designed to bind to HER-2/neu proteins in prepared slides.

Is this antibody reusable, or does it need to be discarded after one use?

This antibody is **intended for single-use only** in a laboratory setting. As a reagent, it is not designed to withstand repeated use or sterilization processes. Laboratories must follow standard reagent handling protocols to ensure accuracy and prevent cross-contamination, as reuse could compromise test reliability or introduce errors in HER-2/neu detection.

What regulatory pathway does the Pathway HER-2/NEU (Clone CB11) Primary Antibody follow?

The antibody holds a **Premarket Approval (PMA)** designation from the FDA (PMA Number: **P990081**), classifying it as a **Class III medical device**. This designation reflects its role in diagnosing conditions that substantially affect patient health—specifically, guiding treatment decisions for breast cancer via HER-2/neu assessment. The approval process ensures its safety, effectiveness, and performance for its intended use in immunohistochemistry.

Are there any special storage requirements for the Pathway HER-2/NEU (Clone CB11) Primary Antibody?

While the provided data does not specify exact storage conditions, **monoclonal antibodies like this one typically require refrigeration (2–8°C)** to maintain stability and efficacy. Laboratories should consult the included **Instructions for Use (IFU)** or manufacturer guidelines for precise storage instructions, including protection from light and freeze-thaw cycles, to preserve the reagent’s integrity for accurate HER-2/neu detection in tissue samples.

This description and any FAQs above were generated automatically from registry data and have not been verified by the manufacturer or by deviCERTS. Always check the official registry entry and the manufacturer's instructions for use before relying on them.

Authorization Coverage (1 country)

Regulatory Authorizations

United States Active

FDA_PMA

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Sources (1)

  • FDA PMA P990081 24 fields · synced Oct 6, 2026